FDAnews Drug Daily Bulletin

Novo Nordisk has discontinued development of one of its four hemophilia drug candidates following data from a Phase IIIa trial that found anti-drug antibodies and further potential risks for hemophilia patients with inhibitors. The trial compared vatreptacog alfa with Novo’s FDA-approved NovoSeven [coagulation factor VIIa (recombinant)] to treat 567 bleeding episodes in 72 hemophiliacs.
Washington Drug Letter